Global Glutamate Receptor Ionotropic NMDA 2B Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Glutamate Receptor Ionotropic NMDA 2B Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Glutamate Receptor Ionotropic NMDA 2B report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Glutamate Receptor Ionotropic NMDA 2B market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Acute Ischemic Stroke and Autism are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Glutamate Receptor Ionotropic NMDA 2B industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Glutamate Receptor Ionotropic NMDA 2B key manufacturers include BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc., Johnson & Johnson, Luc Therapeutics, Inc., NeurOp, Inc, Novartis AG and UCB S.A., etc. BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc. are top 3 players and held % sales share in total in 2022.
Glutamate Receptor Ionotropic NMDA 2B can be divided into JNJ-0808, Neu-2000, NP-10679 and NP-11948, etc. JNJ-0808 is the mainstream product in the market, accounting for % sales share globally in 2022.
Glutamate Receptor Ionotropic NMDA 2B is widely used in various fields, such as Acute Ischemic Stroke, Autism, Brain Ischemia and Burns, etc. Acute Ischemic Stroke provides greatest supports to the Glutamate Receptor Ionotropic NMDA 2B industry development. In 2022, global % sales of Glutamate Receptor Ionotropic NMDA 2B went into Acute Ischemic Stroke filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glutamate Receptor Ionotropic NMDA 2B market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

BioCrea GmbH
Bristol-Myers Squibb Company
Cerecor Inc.
Johnson & Johnson
Luc Therapeutics, Inc.
NeurOp, Inc
Novartis AG
UCB S.A.
Segment by Type
JNJ-0808
Neu-2000
NP-10679
NP-11948
Radiprodil
Others
Acute Ischemic Stroke
Autism
Brain Ischemia
Burns
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Glutamate Receptor Ionotropic NMDA 2B market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Glutamate Receptor Ionotropic NMDA 2B, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Glutamate Receptor Ionotropic NMDA 2B industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Glutamate Receptor Ionotropic NMDA 2B in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Glutamate Receptor Ionotropic NMDA 2B introduction, etc. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Glutamate Receptor Ionotropic NMDA 2B market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Glutamate Receptor Ionotropic NMDA 2B industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Glutamate Receptor Ionotropic NMDA 2B key manufacturers include BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc., Johnson & Johnson, Luc Therapeutics, Inc., NeurOp, Inc, Novartis AG and UCB S.A., etc. BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc. are top 3 players and held % sales share in total in 2022.
Glutamate Receptor Ionotropic NMDA 2B can be divided into JNJ-0808, Neu-2000, NP-10679 and NP-11948, etc. JNJ-0808 is the mainstream product in the market, accounting for % sales share globally in 2022.
Glutamate Receptor Ionotropic NMDA 2B is widely used in various fields, such as Acute Ischemic Stroke, Autism, Brain Ischemia and Burns, etc. Acute Ischemic Stroke provides greatest supports to the Glutamate Receptor Ionotropic NMDA 2B industry development. In 2022, global % sales of Glutamate Receptor Ionotropic NMDA 2B went into Acute Ischemic Stroke filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Glutamate Receptor Ionotropic NMDA 2B market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
BioCrea GmbH
Bristol-Myers Squibb Company
Cerecor Inc.
Johnson & Johnson
Luc Therapeutics, Inc.
NeurOp, Inc
Novartis AG
UCB S.A.
Segment by Type
JNJ-0808
Neu-2000
NP-10679
NP-11948
Radiprodil
Others
Segment by Application
Acute Ischemic Stroke
Autism
Brain Ischemia
Burns
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Glutamate Receptor Ionotropic NMDA 2B market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Glutamate Receptor Ionotropic NMDA 2B, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Glutamate Receptor Ionotropic NMDA 2B industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Glutamate Receptor Ionotropic NMDA 2B in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Glutamate Receptor Ionotropic NMDA 2B introduction, etc. Glutamate Receptor Ionotropic NMDA 2B Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Glutamate Receptor Ionotropic NMDA 2B market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
